GO:1903244 positive regulation of cardiac muscle hypertrophy in response to stress: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903244 describes any process that activates or increases the frequency, rate or extent of cardiac muscle hypertrophy in response to stress.
• Pathological cardiac hypertrophy is driven by neurohormonal and mechanical stress signals that converge on calcium-dependent and PI3K/AKT/mTOR pathways.
• Mitophagy and mitochondrial quality control are essential modulators of stress-induced cardiomyocyte growth and survival.
• Long non-coding RNAs such as LincRNA-p21 and metabolic enzymes such as ACAA2 are emerging regulators of hypertrophic remodeling.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of candidate hypertrophy genes.
• The term is relevant to heart failure, diabetic cardiomyopathy, and ischemia-reperfusion injury, where maladaptive hypertrophy contributes to disease progression.
Description
GO:1903244, positive regulation of cardiac muscle hypertrophy in response to stress, is a biological process term that captures the upstream signals and molecular events that enhance the hypertrophic growth of cardiomyocytes under stress conditions. Cardiac hypertrophy is initially an adaptive response to mechanical load, neurohormonal activation, or metabolic stress, but sustained pathological hypertrophy frequently progresses to heart failure. Understanding the positive regulators of this process is therefore central to identifying therapeutic targets that can preserve cardiac function while limiting maladaptive remodeling. Experimental evidence has implicated calcium handling, PI3K/AKT signaling, mitophagy, and metabolic reprogramming as key nodes that positively regulate stress-induced cardiac hypertrophy. More recently, long non-coding RNAs and mitochondrial proteins have been shown to modulate hypertrophic responses, expanding the list of candidate regulators. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:1903244, its mechanisms, associated genes, disease relevance, and CRISPR-based methods for functional interrogation.
positive regulation of cardiac muscle hypertrophy in response to stress At A Glance
| GO ID | GO:1903244 |
|---|---|
| GO term | positive regulation of cardiac muscle hypertrophy in response to stress |
| Ontology | biological_process |
| Synonym | activation of cardiac muscle hypertrophy in response to stress; up regulation of cardiac muscle hypertrophy in response to stress; up-regulation of cardiac muscle hypertrophy in response to stress; upregulation of cardiac muscle hypertrophy in response to stress |
| Major function | Enhances the initiation and progression of cardiac muscle hypertrophy under stress conditions |
| Related processes | Calcium signaling, PI3K/AKT/mTOR signaling, mitophagy, metabolic reprogramming |
| Disease relevance | Heart failure, diabetic cardiomyopathy, ischemia-reperfusion injury |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, proteomics, imaging |
What Is GO:1903244?
GO:1903244 is defined by QuickGO as any process that activates or increases the frequency, rate or extent of cardiac muscle hypertrophy in response to stress. In practical terms, it encompasses the signaling events, transcriptional programs, and cellular adaptations that amplify the growth response of cardiac muscle cells when they are exposed to stressors such as pressure overload, neurohormonal stimulation, or metabolic challenge. This term is a positive regulation term, meaning it specifically annotates gene products and pathways that promote, rather than suppress, stress-induced cardiac hypertrophy.
Why Is positive regulation of cardiac muscle hypertrophy in response to stress Important in Cell Biology?
GO:1903244 is important because positive regulators of stress-induced cardiac hypertrophy are attractive targets for therapeutic intervention in heart failure and related cardiomyopathies. While hypertrophy can be initially compensatory, sustained activation of pro-hypertrophic pathways contributes to adverse remodeling, arrhythmia, and contractile dysfunction. Identifying the specific genes and signaling nodes that positively regulate this process can reveal biomarkers and druggable targets. Moreover, the interplay between hypertrophy and mitochondrial quality control, as exemplified by mitophagy and metabolic enzymes, highlights the need to understand how positive regulation integrates with cellular stress responses.
• Defines the molecular basis of maladaptive cardiac growth in heart failure.
• Links neurohormonal and mechanical stress to cardiomyocyte growth programs.
• Highlights calcium-dependent signaling as a positive regulator of hypertrophy.
• Implicates PI3K/AKT pathway modulation in stress-induced cardiomyocyte responses.
• Connects mitophagy and mitochondrial dysfunction to hypertrophic remodeling.
• Reveals metabolic enzymes such as ACAA2 as regulators of cardiomyocyte hypertrophy.
• Positions long non-coding RNAs like LincRNA-p21 as modulators of cardiac hypertrophy.
• Provides a framework for CRISPR-based causal gene validation.
• Supports development of targeted therapies for diabetic cardiomyopathy.
• Guides experimental models for studying stress-induced cardiac hypertrophy.
What Happens During positive regulation of cardiac muscle hypertrophy in response to stress?
Stress sensing and calcium signaling
In simple terms: When the heart is stressed, calcium signals inside heart muscle cells go up and trigger growth programs.
Mechanical stretch and neurohormonal stress increase intracellular calcium transients in cardiomyocytes, which activates calcineurin/NFAT and CaMKII signaling to promote hypertrophic gene expression. Calcium-dependent pathways are among the earliest positive regulators of cardiac muscle hypertrophy in response to stress, translating physical and chemical stress into transcriptional changes. This calcium sensitivity makes the process highly responsive to hemodynamic load and circulating factors.
PI3K/AKT and mTOR activation
In simple terms: Growth factor pathways act like a green light for heart muscle cells to enlarge.
Neurohormonal and growth factor stimulation activates PI3K/AKT signaling, which in turn engages mTOR and downstream effectors to increase protein synthesis and cell size. Pharmacological modulation of PI3K/AKT has been shown to mitigate cellular stress and inflammation in cardiomyocytes, underscoring the pathway's role in positive regulation of hypertrophy. This axis is a central node where stress signals converge to enhance cardiac muscle hypertrophy.
Mitophagy and mitochondrial quality control
In simple terms: Cells recycle damaged mitochondria to keep the heart working during stress.
Mitophagy is essential for maintaining cardiac function during metabolic stress such as high-fat diet-induced diabetic cardiomyopathy. Impairment of mitophagy can exacerbate mitochondrial dysfunction and promote maladaptive hypertrophic remodeling. Conversely, enhancing mitophagy through AMPK-Parkin-ACSL4 signaling has been shown to mitigate myocardial hypertrophy, indicating that mitochondrial quality control intersects with positive regulation of cardiac hypertrophy.
Metabolic reprogramming and lactylation
In simple terms: Changes in how heart cells use energy can drive them to grow under stress.
Metabolic enzymes such as ACAA2 undergo lactylation and altered expression in phenylephrine-induced cardiomyocyte hypertrophy, linking metabolic stress to mitochondrial dysfunction and hypertrophic growth. This suggests that metabolic reprogramming is not merely a consequence but a positive regulator of stress-induced cardiac hypertrophy. Targeting metabolic nodes may therefore modulate the hypertrophic response.
Non-coding RNA and transcriptional control
In simple terms: Long non-coding RNAs can turn up or down the genes that make heart cells grow.
LincRNA-p21 has been shown to promote cardiac hypertrophy, and its therapeutic inhibition protects against hypertrophic remodeling. This illustrates that non-coding RNAs can act as positive regulators within the GO:1903244 process by modulating transcriptional and post-transcriptional networks. Integrating non-coding RNA regulation with classical signaling pathways provides a more complete picture of stress-induced cardiac hypertrophy.
Key Genes Involved in GO:1903244 positive regulation of cardiac muscle hypertrophy in response to stress
The following genes and proteins have been experimentally implicated in positive regulation of cardiac muscle hypertrophy in response to stress, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AKT1 | Serine/threonine kinase that promotes protein synthesis and cardiomyocyte growth | Central node in PI3K/AKT-driven hypertrophy; target for pathway modulation |
| MTOR | Kinase that integrates growth signals to enhance translation and cell size | Key effector of hypertrophic growth; rapamycin-sensitive |
| CAMK2 | Calcium/calmodulin-dependent kinase that transduces stress signals | Links calcium handling to hypertrophic gene programs |
| PPP3CA (calcineurin) | Phosphatase that activates NFAT transcription factors | Calcium-dependent positive regulator of hypertrophy |
| NFATC | Transcription factor family activated by calcineurin | Drives hypertrophic gene expression |
| PRKAA1/2 (AMPK) | Energy sensor that modulates mitophagy and metabolism | Regulates mitophagy-ferroptosis balance in hypertrophy |
| PRKN (Parkin) | E3 ubiquitin ligase involved in mitophagy | Mediates mitochondrial quality control in hypertrophic stress |
| ACSL4 | Enzyme involved in lipid metabolism and ferroptosis | Part of AMPK-Parkin-ACSL4 axis in myocardial hypertrophy |
| ACAA2 | Mitochondrial enzyme subject to lactylation | Mediates mitochondrial dysfunction in phenylephrine-induced hypertrophy |
| LincRNA-p21 | Long non-coding RNA that promotes hypertrophy | Therapeutic inhibition protects against cardiac hypertrophy |
| SIRT3 | Mitochondrial deacetylase that supports mitochondrial function | Implicated in age-related mitochondrial decline; relevant to cardiac stress |
| PGC1A (PPARGC1A) | Transcriptional coactivator of mitochondrial biogenesis | Downstream of SIRT3; supports mitochondrial function under stress |
| HSF1 | Stress-responsive transcription factor | Regulates SIRT3-PGC1α axis in muscle aging; potential cardiac relevance |
| PIK3CA | Catalytic subunit of PI3K | Upstream activator of AKT in stress responses |
| MAPK1/3 (ERK) | Kinases downstream of growth factor signaling | Contribute to hypertrophic gene expression |
| GATA4 | Transcription factor regulating cardiac genes | Cooperates with NFAT in hypertrophy |
| MEF2 | Transcription factor family in cardiac growth | Integrates stress signals into hypertrophic program |
| MYH7 | Sarcomeric protein and hypertrophy marker | Readout of hypertrophic remodeling |
How Is positive regulation of cardiac muscle hypertrophy in response to stress Regulated?
Positive regulation of cardiac muscle hypertrophy in response to stress is controlled by a multilayered network. Upstream, mechanical stretch and neurohormonal factors activate calcium-dependent calcineurin/NFAT and CaMKII signaling. Growth factor pathways converge on PI3K/AKT/mTOR to enhance protein synthesis and cell growth. Mitochondrial quality control through mitophagy modulates the hypertrophic response, with AMPK-Parkin-ACSL4 signaling influencing both mitophagy and ferroptosis. Metabolic enzymes such as ACAA2 and their post-translational modifications, including lactylation, further tune mitochondrial function and hypertrophic growth. Non-coding RNAs like LincRNA-p21 add an additional layer of transcriptional and post-transcriptional regulation. Together, these pathways determine whether hypertrophy remains adaptive or becomes maladaptive.
positive regulation of cardiac muscle hypertrophy in response to stress and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LincRNA-p21 | Cardiac hypertrophy and heart failure | Knockout and overexpression in cardiomyocytes; transverse aortic constriction model |
| ACAA2 | Phenylephrine-induced cardiomyocyte hypertrophy and mitochondrial dysfunction | Point mutation of lactylation sites; overexpression in H9c2 or primary cardiomyocytes |
| PRKN (Parkin) | Mitophagy dysfunction in myocardial hypertrophy | Knockout in cardiomyocytes; AMPK-Parkin-ACSL4 pathway interrogation |
| AKT1 | PI3K/AKT-driven hypertrophy and cellular stress | Overexpression and point-mutation models; dapagliflozin treatment |
| SIRT3 | Age-associated mitochondrial decline and cardiac stress | Knockout and knock-in models; HSF1-SIRT3-PGC1α axis studies |
Heart failure and maladaptive hypertrophy
Sustained activation of positive regulators of cardiac hypertrophy contributes to adverse remodeling and progression to heart failure. Targeting pro-hypertrophic signaling, such as PI3K/AKT or LincRNA-p21, has been explored as a therapeutic strategy to limit maladaptive growth. Understanding GO:1903244 helps identify which nodes can be safely modulated to preserve cardiac function.
Diabetic cardiomyopathy
Mitophagy is essential for maintaining cardiac function during high-fat diet-induced diabetic cardiomyopathy, and its impairment exacerbates mitochondrial dysfunction and hypertrophy. This links metabolic stress to positive regulation of cardiac hypertrophy and suggests that enhancing mitophagy could be protective.
Ischemia-reperfusion and metabolic stress
Metabolic and oxidative stress during ischemia-reperfusion can activate hypertrophic signaling and mitochondrial dysfunction. The AMPK-Parkin-ACSL4 pathway modulates mitophagy and ferroptosis, influencing cardiomyocyte survival and hypertrophy under stress. These mechanisms are relevant to developing therapies for ischemic heart disease.
From positive regulation of cardiac muscle hypertrophy in response to stress-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for stress-induced hypertrophy? | CRISPR knockout in cardiomyocytes or mouse heart |
| Does a specific phosphorylation or lactylation site regulate hypertrophy? | Point-mutation knock-in of the modified residue |
| Does a risk variant alter hypertrophic signaling? | Knock-in of the human variant in a cardiac cell line or mouse |
| Where and when is the protein expressed during stress? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of the gene drive hypertrophy? | Transgenic or viral overexpression in cardiomyocytes |
| Can pathway inhibitors block positive regulation? | Pharmacological intervention in wild-type and knockout models |
How to Study the positive regulation of cardiac muscle hypertrophy in response to stress Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes | Identify pro-hypertrophic genes and lncRNAs |
| Proteomics | Protein abundance and modifications | Detect ACAA2 lactylation in hypertrophy |
| Mitophagy flux assay | Autophagic clearance of mitochondria | Assess mitochondrial quality control under stress |
| Confocal imaging | Cardiomyocyte size and sarcomere organization | Quantify hypertrophic growth |
| Calcium transient imaging | Intracellular calcium handling | Evaluate calcium-dependent signaling |
| Echocardiography | Cardiac structure and function | Monitor hypertrophy in animal models |
| Western blot | Protein expression and phosphorylation | Validate pathway activation (AKT, AMPK) |
| CRISPR screening | Gene essentiality in hypertrophy | Discover novel positive regulators |
Transcriptomic and non-coding RNA profiling
RNA-seq and targeted non-coding RNA profiling can identify transcriptional changes and long non-coding RNAs such as LincRNA-p21 that positively regulate cardiac hypertrophy. Comparing stressed versus unstressed cardiomyocytes reveals candidate regulators within GO:1903244.
Proteomics and post-translational modification analysis
Mass spectrometry-based proteomics can detect changes in protein abundance and modifications such as lactylation on ACAA2 during hypertrophic stress. This approach helps map the molecular effectors of positive regulation.
Mitophagy and mitochondrial function assays
Mitophagy flux assays, mitochondrial respiration measurements, and imaging of autophagosomes can assess mitochondrial quality control in hypertrophic models. These methods link mitochondrial dysfunction to positive regulation of cardiac hypertrophy.
Imaging and functional phenotyping
Confocal imaging of cardiomyocyte size, sarcomeric organization, and calcium transients provides direct readouts of hypertrophy. Echocardiography in animal models assesses functional consequences of hypertrophic remodeling.
How CRISPR Can Be Used to Study GO:1903244 positive regulation of cardiac muscle hypertrophy in response to stress
Knockout
CRISPR knockout of candidate genes such as LincRNA-p21 or PRKN can test whether they are required for stress-induced cardiac hypertrophy. Loss-of-function models help distinguish drivers from bystanders in the hypertrophic response.
Point Mutation
Point mutations can be introduced to ablate specific phosphorylation or lactylation sites, as exemplified by ACAA2 lactylation studies. This allows precise interrogation of post-translational regulation within GO:1903244.
Knock-in
Knock-in of disease-associated variants or tagged alleles enables tracking of protein localization and function during hypertrophic stress. This is particularly useful for validating human genetic findings in cardiac models.
Overexpression
Overexpression of candidate genes such as AKT1 or LincRNA-p21 can drive hypertrophy in the absence of external stress, confirming sufficiency. Combining overexpression with pathway inhibitors helps define mechanism.
How EDITGENE Supports positive regulation of cardiac muscle hypertrophy in response to stress Research
Researchers studying positive regulation of cardiac muscle hypertrophy in response to stress-related genes often need to determine whether a candidate gene is causally involved in the hypertrophic response or merely a correlative marker. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to enable such causal interrogation, from knockout to precise point mutations and knock-in reporters.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of cardiac muscle hypertrophy in response to stress research.
Frequently Asked Questions About positive regulation of cardiac muscle hypertrophy in response to stress
What is GO:1903244?
GO:1903244 is the Gene Ontology term for positive regulation of cardiac muscle hypertrophy in response to stress, describing processes that enhance stress-induced cardiac muscle growth.
What genes are involved in positive regulation of cardiac muscle hypertrophy in response to stress?
Key genes include AKT1, MTOR, CAMK2, PPP3CA, PRKN, ACAA2, and LincRNA-p21, among others.
How is cardiac muscle hypertrophy in response to stress regulated?
It is regulated by calcium signaling, PI3K/AKT/mTOR, mitophagy, metabolic reprogramming, and non-coding RNAs.
What diseases are associated with GO:1903244?
Heart failure, diabetic cardiomyopathy, and ischemia-reperfusion injury are associated with maladaptive cardiac hypertrophy.
What research methods are used to study positive regulation of cardiac muscle hypertrophy?
RNA-seq, proteomics, mitophagy assays, imaging, echocardiography, and CRISPR screens are commonly used.
How can CRISPR help study cardiac hypertrophy genes?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in cardiomyocytes.
What is the role of mitophagy in cardiac hypertrophy?
Mitophagy maintains mitochondrial quality control and its impairment exacerbates maladaptive hypertrophy under stress.
What is LincRNA-p21 and how does it affect hypertrophy?
LincRNA-p21 is a long non-coding RNA that promotes cardiac hypertrophy; its inhibition protects against hypertrophic remodeling.
What is the role of ACAA2 in cardiomyocyte hypertrophy?
ACAA2 lactylation and expression mediate mitochondrial dysfunction in phenylephrine-induced cardiomyocyte hypertrophy.
How does PI3K/AKT signaling contribute to cardiac hypertrophy?
PI3K/AKT activation promotes protein synthesis and cardiomyocyte growth under stress, and its modulation can mitigate cellular stress.
Conclusion
GO:1903244, positive regulation of cardiac muscle hypertrophy in response to stress, encompasses a complex network of calcium signaling, PI3K/AKT/mTOR, mitophagy, metabolic reprogramming, and non-coding RNA regulation. These pathways determine whether the heart adapts or succumbs to stress, making them critical targets for therapeutic intervention in heart failure and related cardiomyopathies. CRISPR-based models provide powerful tools to dissect the causal roles of individual genes within this process, accelerating the translation of mechanistic insights into clinical strategies.
References
- 1. Nakamura M et al.. 2018. Mechanisms of physiological and pathological cardiac hypertrophy.. Nat Rev Cardiol 15(7):387-407 PMID: 29674714
- 2. Tong M et al.. 2019. Mitophagy Is Essential for Maintaining Cardiac Function During High Fat Diet-Induced Diabetic Cardiomyopathy.. Circ Res 124(9):1360-1371 PMID: 30786833
- 3. Wang Y et al.. 2024. Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy.. Circ Res 135(3):434-449 PMID: 38864216
- 4. Zhang J et al.. 2026. Skeletal Muscle HSF1 Alleviates Age-Associated Sarcopenia and Mitochondrial Function Decline via SIRT3-PGC1α Axis.. Adv Sci (Weinh) 13(11):e10368 PMID: 41400028
- 5. Calaghan SC et al.. 1999. The role of calcium in the response of cardiac muscle to stretch.. Prog Biophys Mol Biol 71(1):59-90 PMID: 10070212
- 6. Alsereidi FR et al.. 2024. Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells.. Cardiovasc Diabetol 23(1):388 PMID: 39472869
- 7. Guo Y et al.. 2025. ACAA2 lactylation and expression mediate mitochondrial dysfunction in phenylephrine-induced cardiomyocyte hypertrophy.. Biochem Biophys Res Commun 781:152518 PMID: 40858063
- 8. Wang Y et al.. 2026. Paeoniflorin mitigates myocardial hypertrophy by regulating mitophagy and ferroptosis mediated by mitochondria-associated AMPK-Parkin-ACSL4 pathway.. Free Radic Biol Med 245:98-114 PMID: 41443335
